Works cited by this work

130 works

Work: CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott +26
Article20109 citations
ABI
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Review article20127 citations
ABI
The role of regulatory T cells in the pathogenesis and treatment of prostate cancer
Vahid Karpisheh, Seyedeh Mahboubeh Mousavi, Parinaz Naghavi Sheykholeslami +6
Review article20216 citations
ABI
Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells
Mehrdad Fathi, Simin Bahmanpour, Asal Barshidi +12
Article20215 citations
ABI
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer
Vahid Karpisheh, Afshin Nikkhoo, Mohammad Hojjat‐Farsangi +7
Review article20195 citations
ABI
EP4 receptor as a novel promising therapeutic target in colon cancer
Vahid Karpisheh, Navneet Joshi, Angelina Olegovna Zekiy +5
Review article20205 citations
ABI
The role of Th17 cells in the pathogenesis and treatment of breast cancer
Vahid Karpisheh, Majid Ahmadi, Kazem Abbaszadeh‐Goudarzi +5
Review article20225 citations
ABI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang +32
Article20155 citations
ABI
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan, Lisa M. Coussens
Review article20124 citations
ABI
Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles
Abbas Ali Hosseinpour Feizi, Sajjad Vakili‐Samiani, Vahid Karpisheh +11
Article20224 citations
ABI
The tumor microenvironment
Nicole Anderson, M. Celeste Simon
Article20204 citations
ABI
RETRACTED: Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression
Navneet Joshi, Farnaz Hajizadeh, Ehsan Ansari Dezfouli +11
Article20214 citations
ABI
The molecular biology and therapeutic potential of Nrf2 in leukemia
Atefeh Khodakarami, Sara Adibfar, Vahid Karpisheh +6
Review article20224 citations
ABI
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Philip W. Kantoff, Celestia S. Higano, Neal D. Shore +10
Article20103 citations
ABI
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27
Article20123 citations
ABI
Innate immune cells in the tumor microenvironment
Ming O. Li, Natalie K. Wolf, David H. Raulet +8
Article20213 citations
ABI
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison
Article19963 citations
ABI
T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer
Mehrdad Fathi, Inna Pustokhina, Sergey V. Kuznetsov +5
Review article20213 citations
ABI
Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer
Sepideh Izadi, Mohammad Hojjat Farsang, Vahid Karpisheh +1
Article20233 citations
ABI
Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1
Shiva Abolhasani, Armin Mahmoud Salehi Khesht, Atefeh Khodakarami +13
Article20253 citations
ABI
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lucia Lisi, Pedro Miguel Lacal, Maria Martire +2
Review article20212 citations
ABI
Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response
Richard P. Junghans, Qiangzhong Ma, Ritesh Rathore +8
Article20162 citations
ABI
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Mamello Sekhoacha, Keamogetswe Riet, Paballo Motloung +3
Review article20222 citations
ABI
2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
Oskar Bergengren, Kelly R. Pekala, Konstantina Matsoukas +9
Review article20232 citations
ABI
miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro
Markus Krebs, Antonio Giovanni Solimando, Charis Kalogirou +10
Article20202 citations
ABI